Madrigal Pharma (MDGL) Tops Q1 EPS by 94c

Madrigal Pharma (NASDAQ: MDGL) reported Q1 EPS of ($3.25), $0.94 better than the analyst estimate of ($4.19). Revenue for the quarter came in at $311.34 million versus the consensus estimate of $301.29 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• GameStop drops Cohen’s $35B pay plan to focus on eBay acquisition
• Nike updates Q4 fiscal 2026 outlook with tariff refund benefit